Please use this identifier to cite or link to this item: https://doi.org/10.1186/s13195-020-00694-3
DC FieldValue
dc.titleImmunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer's disease and vascular cognitive impairment
dc.contributor.authorChua, Xin Ying
dc.contributor.authorChai, Yuek Ling
dc.contributor.authorChew, Wee Siong
dc.contributor.authorChong, Joyce R
dc.contributor.authorAng, Hui Li
dc.contributor.authorXiang, Ping
dc.contributor.authorCamara, Kaddy
dc.contributor.authorHowell, Amy R
dc.contributor.authorTorta, Federico
dc.contributor.authorWenk, Markus R
dc.contributor.authorHilal, Saima
dc.contributor.authorVenketasubramanian, Narayanaswamy
dc.contributor.authorChen, Christopher P
dc.contributor.authorHerr, Deron R
dc.contributor.authorLai, Mitchell KP
dc.date.accessioned2021-04-05T08:46:25Z
dc.date.available2021-04-05T08:46:25Z
dc.date.issued2020-09-30
dc.identifier.citationChua, Xin Ying, Chai, Yuek Ling, Chew, Wee Siong, Chong, Joyce R, Ang, Hui Li, Xiang, Ping, Camara, Kaddy, Howell, Amy R, Torta, Federico, Wenk, Markus R, Hilal, Saima, Venketasubramanian, Narayanaswamy, Chen, Christopher P, Herr, Deron R, Lai, Mitchell KP (2020-09-30). Immunomodulatory sphingosine-1-phosphates as plasma biomarkers of Alzheimer's disease and vascular cognitive impairment. ALZHEIMERS RESEARCH & THERAPY 12 (1). ScholarBank@NUS Repository. https://doi.org/10.1186/s13195-020-00694-3
dc.identifier.issn17589193
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/188320
dc.description.abstractBackground: There has been ongoing research impetus to uncover novel blood-based diagnostic and prognostic biomarkers for Alzheimer's disease (AD), vascular dementia (VaD), and related cerebrovascular disease (CEVD)-associated conditions within the spectrum of vascular cognitive impairment (VCI). Sphingosine-1-phosphates (S1Ps) are signaling lipids which act on the S1PR family of cognate G-protein-coupled receptors and have been shown to modulate neuroinflammation, a process known to be involved in both neurodegenerative and cerebrovascular diseases. However, the status of peripheral S1P in AD and VCI is at present unclear. Methods: We obtained baseline bloods from individuals recruited into an ongoing longitudinal cohort study who had normal cognition (N = 80); cognitive impairment, no dementia (N = 160); AD (N = 113); or VaD (N = 31), along with neuroimaging assessments of cerebrovascular diseases. Plasma samples were processed for the measurements of major S1P species: d16:1, d17:1, d18:0, and d18:1, along with pro-inflammatory cytokines interleukin (IL)-6, IL-8, and tumor necrosis factor (TNF). Furthermore, in vitro effects of S1Ps on cytokine expression were also studied in an astrocytoma cell line and in rodent primary astrocytes. Results: Of the S1Ps species measured, only d16:1 S1P was significantly reduced in the plasma of VaD, but not AD, patients, while the d18:1 to d16:1 ratios were increased in all cognitive subgroups (CIND, AD, and VaD). Furthermore, d18:1 to d16:1 ratios correlated with levels of IL-6, IL-8, and TNF. In both primary astrocytes and an astroglial cell line, treatment with d16:1 or d18:1 S1P resulted in the upregulation of mRNA transcripts of pro-inflammatory cytokines, with d18:1 showing a stronger effect than d16:1. Interestingly, co-treatment assays showed that the addition of d16:1 reduced the extent of d18:1-mediated gene expression, indicating that d16:1 may function to "fine-tune"the pro-inflammatory effects of d18:1. Conclusion: Taken together, our data suggest that plasma d16:1 S1P may be useful as a diagnostic marker for VCI, while the d18:1 to d16:1 S1P ratio is an index of dysregulated S1P-mediated immunomodulation leading to chronic inflammation-associated neurodegeneration and cerebrovascular damage.
dc.language.isoen
dc.publisherBMC
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectClinical Neurology
dc.subjectNeurosciences
dc.subjectNeurosciences & Neurology
dc.subjectAlzheimer's disease
dc.subjectBiomarkers
dc.subjectImmunomodulation
dc.subjectNeuroinflammation
dc.subjectSphingosine-1-phosphate
dc.subjectVascular cognitive impairment
dc.subjectBLOOD-BASED BIOMARKERS
dc.subjectSMALL VESSEL DISEASE
dc.subjectCEREBROVASCULAR-DISEASE
dc.subjectDEMENTIA
dc.subjectSPHINGOLIPIDS
dc.subjectINHIBITION
dc.subjectFINGOLIMOD
dc.subjectDIAGNOSIS
dc.subjectMODEL
dc.typeArticle
dc.date.updated2021-04-02T19:38:21Z
dc.contributor.departmentDEPT OF BIOCHEMISTRY
dc.contributor.departmentDEPT OF PHARMACOLOGY
dc.description.doi10.1186/s13195-020-00694-3
dc.description.sourcetitleALZHEIMERS RESEARCH & THERAPY
dc.description.volume12
dc.description.issue1
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
66 Chua Herr S1P AD VCI MACC ART 2020.pdf1.2 MBAdobe PDF

OPEN

PublishedView/Download

SCOPUSTM   
Citations

12
checked on Jun 28, 2022

Page view(s)

148
checked on Jun 23, 2022

Download(s)

1
checked on Jun 23, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.